ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

0HD2 Alnylam Pharmaceuticals Inc

100.80
0.00 (0.00%)
May 16 2024 - Closed
Delayed by 15 minutes

Income Statement

Balance Sheet

Cash Flow

Year End December 30 2023 20162017201820192020202120222023
USD ($)USD ($)USD ($)USD ($)USD ($)USD ($)USD ($)USD ($)
Total Revenue 47.16M89.91M74.91M219.75M492.85M844.29M1.04B1.83B
Operating Income -424.59M-500.09M-814.67M-939.43M-828.44M-708.65M-785.07M-282.18M
Pre Tax Income -410.11M-490.87M-760.67M-885.25M-855.6M-852.14M-1.13B-433.52M
Net Income -410.11M-490.87M-761.5M-886.12M-858.28M-852.82M-1.13B-440.24M
Preferred Dividends 00000000
Basic Earnings Per Share (EPS) -4.772-4.925-7.526-7.898-7.372-7.096-9.128-3.508
EBIT -418.42M-503.11M-789.94M-918.7M-782.91M-727.96M-791.28M-407.86M
EBITDA -414.99M-488.19M-801.87M-922.83M-798.24M-661.09M-740.6M-228.12M